Two‐Step MRI and Clinical Model for Detecting At‐Risk Steatohepatitis in Metabolic Liver Disease
Liver International · 2026
DOI: 10.1111/liv.70541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Mingkai Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Research Council.
Abstract (Originalsprache)
Background & Aims Identifying at‐risk metabolic dysfunction‐associated steatohepatitis (MASH with ≥ stage 2 fibrosis) is critical. While the steatosis‐associated fibrosis estimator (SAFE) score effectively stages significant fibrosis (≥ stage 2 fibrosis) and the MR‐MASH score detects MASH, their combined performance remains unclear.
Methods
This two‐part study evaluated serial combinations of non‐invasive tests for at‐risk MASH in clinical and population‐based settings. In part 1, we analysed 286 patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) from an Asian center with biopsy‐proven diagnoses. Four two‐step strategies were compared. In part 2, 495 MASLD patients from the UK Biobank with corrected T1 values were used to validate selected strategies.
Results
In part 1, the combination of SAFE followed by the MR‐MASH for at‐risk MASH (strategy A) showed higher accuracy than SAFE followed by FibroScan‐AST (FAST) score and FIB‐4 followed by FAST (87.8% vs. 69.1% and 71.2%, both p < 0.01) and similar misclassification rates (10.1% vs. 11.5% and 11.5%, both p = 0.83). Compared with Fibrosis‐4 followed by magnetic resonance‐based model (strategy B), strategy A had a higher accuracy (88.5% vs. 83.9%, p < 0.01) and a lower misclassification rate (9.1% vs. 12.9%, p < 0.01). In part 2, strategy A maintained a high negative predictive value (99.7%) and showed lower misclassification than strategy B (3.6% vs. 5.7%, p = 0.03), with similar accuracy (82.6% vs. 82.0%, p = 0.74) and indeterminate rates (13.7% vs. 12.3%, p = 0.19).
Conclusions
Serial combination of SAFE and MR‐MASH performs well in predicting at‐risk MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
- Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
- Department of Radiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
- Department of Pathology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
- Department of Gastroenterology and Endoscopy Center, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, People's Republic of China.
- Department of Biostatistics and Epidemiology, Public Health College, Shenzhen University Medical School, Shenzhen, People's Republic of China.
ORCID-Profile: Mingkai Li, Hongsheng Yu, Yidong Yang, Qingtian Luo, Fulan Hu, Bin Wu
Förderung
- National Natural Science Foundation of China
- Medical Research Council
Zitieren
APA
Li, M., Chen, Z., Chen, H., Zong, X., Ren, Y., Yu, H., Lin, W., Chen, J., Yang, Y., Luo, Q., Hu, F., & Wu, B. (2026). Two‐Step MRI and Clinical Model for Detecting At‐Risk Steatohepatitis in Metabolic Liver Disease. Liver International. https://doi.org/10.1111/liv.70541
Vancouver
Li M, Chen Z, Chen H, Zong X, Ren Y, Yu H, et al. Two‐Step MRI and Clinical Model for Detecting At‐Risk Steatohepatitis in Metabolic Liver Disease. Liver International. 2026. doi:10.1111/liv.70541
BibTeX
@article{Li2026,
author = {Li, Mingkai and Chen, Zebin and Chen, Haimei and Zong, Xiaodan and Ren, Yuexiang and Yu, Hongsheng and Lin, Weichun and Chen, Jianning and Yang, Yidong and Luo, Qingtian and Hu, Fulan and Wu, Bin},
title = {Two‐Step MRI and Clinical Model for Detecting At‐Risk Steatohepatitis in Metabolic Liver Disease},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70541}
}
EUVIMED